PHARMACIST TECHNICIAN POCKET GUIDE

INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

RSV STOPS HERE



AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

- individuals 60 years of age and older;
- individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.

Vaccination may not protect all recipients.[1]

Not an actual patient.

Important Safety Information

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED)

GSK

The Potential Impact of RSV

RSV is a common and contagious virus that usually causes mild, cold-like symptoms. But sometimes, RSV infection can progress to more severe disease involving the lower respiratory tract.[2]

Older adults, including those with certain medical conditions, are at increased risk for severe RSV infection.[2]

Not an actual patient.

Are Your Patients Aware of the Risks of RSV?
Talk to them today about vaccination against RSV with AREXVY.

Important Safety Information (cont.)

- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting

The CDC Updates RSV Vaccine Recommendation

The CDC recommends:

Adults 75 years of age and older receive a single dose of RSV vaccine[3]

Adults 60-74 years of age who are at increased risk of severe RSV disease receive a single dose of RSV vaccine[3]

Please see CDC for list of CDC-identified risk factors for severe RSV disease

CDC=Centers for Disease Control and Prevention.

Not an actual patient.

Important Safety Information (cont.)

- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

The Potential Impact of RSV

Not an actual patient.

RSV is a common and contagious virus that usually causes mild, cold-like symptoms. But sometimes, RSV infection can progress to more severe disease involving the lower respiratory tract.[2]

Older adults, including those with certain medical conditions, are at increased risk for severe RSV infection.[2]

Are Your Patients Aware of the Risks of RSV?
Talk to them today about vaccination against RSV with AREXVY.

Important Safety Information (cont.)

- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting

Storage[1]

AREXVY should be refrigerated.
DO NOT FREEZE (discard if frozen).

Store in the original package to protect vials from light.

Store adjuvant suspension component vials and lyophilized antigen component vials between 2 °C and 8 °C (36 °F and 46 °F) before reconstitution.

After reconstitution, administer immediately or store between 2 °C and 8 °C (36 °F and 46 °F) or at room temperature up to 25 °C (77 °F) for up to 4 hours prior to use.

Protect from light.

Discard reconstituted vaccine if not used within 4 hours or has been frozen.

Important Safety Information (cont.)

- In adults 60 years of age and older, the most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)

Dosing and Administration[1]

AREXVY is supplied in 2 vials that must be reconstituted prior to administration.

Administer 1 dose (0.5 mL) of AREXVY as an intramuscular injection.

Please refer to the full Prescribing Information for AREXVY for comprehensive details.

Coadministration of AREXVY in Adults 60+ With Other Adult Vaccines

- According to the US Prescribing Information, AREXVY can be coadministered with flu vaccination. Data are not available for concomitant administration with other vaccines[1]
- According to the CDC, coadministration of RSV vaccines with other adult vaccines during the same visit is acceptable[4]
- Available data on immunogenicity of coadministration of RSV vaccines and other vaccines are currently limited[3]



CDC=Centers for Disease Control and Prevention.

Not an actual patient.

Important Safety Information (cont.)

- In adults 50 through 59 years of age, the most commonly reported adverse reactions (≥10%) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

Download helpful resources at AREXVYhcp.com

Important Safety Information (cont.)

- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see additional Important Safety Information throughout and accompanying full Prescribing Information for AREXVY.

References: 1. Prescribing Information for AREXVY. **2.** Respiratory syncytial virus infection (RSV). Clinical overview of RSV. Centers for Disease Control and Prevention. Accessed July 11, 2024. https://www.cdc.gov/rsv/hcp/clinical-overview/ **3.** Healthcare providers: RSV vaccination for adults 60 years of age and over. Centers for Disease Control and Prevention. Accessed July 9, 2024. https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html **4.** Britton A, Roper LE, Kotton CN, et al. Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2024. *MMWR*. Published online August 6, 2024. doi:10.15585/mmwr.mm7332e1

PMUS-RSALBND240013 September 2024
Produced in USA. 0002-0031-79

AREXVY
(RESPIRATORY SYNCYTIAL VIRUS VACCINE, ADJUVANTED)

GSK